It's important to recognize some of the barriers that are faced. Overcoming them will require interactions between Health Canada, individual food companies, and groups of food companies. This is going to require the hiring of trained personnel. There are going to have to be negotiations about the targets and timelines, and this will require technical expertise in the relevant foods. That will mean hiring people and obtaining monetary resources.
The actual surveillance is complex and has to be representative of the Canadian population. There is a mechanism for that: the Canadian health measures survey. It's ongoing but it will need additional resources for the sodium monitoring—and that's on top of the education. This will probably come to $10 million to $20 million a year.
The cost savings from reduced need for antihypertensive agents will be around $300 million a year. So there is a monetary investment, but there is a direct, accelerated return on investment.